8-K: Monogram Technologies Closes Oversubscribed $13 Million Offering and Receives FDA Information Request

Monogram Technologies successfully closed a $13 million Series D preferred stock offering and received an Additional Information Request from the FDA regarding its mBs TKA System.

Summary

• Monogram Technologies closed its Series D preferred stock offering on October 1, 2024, raising approximately $13 million in gross proceeds.
• The offering included 5,790,479 units, each consisting of one share of Series D preferred stock and one common stock purchase warrant.
• Net proceeds from the offering are estimated to be $11.7 million after deducting selling agent fees.
• The company received an Additional Information Request (AIR) from the FDA on September 30, 2024, regarding its 510(k) submission for the mBs TKA System.
• The FDA has placed the application on hold, requiring a complete response to the AIR within 180 days.
• The first dividend on the Series D preferred stock, at $0.033 per share, is scheduled for October 15, 2024, covering the period from August 9, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. The successful capital raise is positive, but the FDA's request for additional information and the resulting delay are significant negatives. The company's future prospects are uncertain, leading to a neutral sentiment.

Positives

• The company successfully closed an oversubscribed offering, indicating strong investor confidence.
• The $11.7 million in net proceeds provides a significant cash runway for the company's near-term commercialization milestones.
• Management believes the FDA feedback provides a framework to execute and reiterated an accommodative posture toward clinical data obtained from Indian trials.
• The company is pursuing a parallel submission for its active modality with OUS clinical data.

Negatives

• The FDA's Additional Information Request (AIR) has placed the mBs TKA System application on hold.
• The company has 180 days to respond to the AIR, or the application may be withdrawn.
• The company cannot estimate the timing or assure the ability to obtain FDA clearances.

Risks

• The company's lack of profitability and need for additional capital to grow its business is a risk.
• The company's dependence on partners to further the development of its product candidates is a risk.
• There are uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new product.
• The outcome of pending or future litigation is a risk.

Future Outlook

The company intends to use the net proceeds for general corporate purposes, operational needs, new technology development, and potential acquisitions. They are also working to obtain FDA clearance for their 510(k) submission and will pursue a submission for its active modality with OUS clinical data.

Management Comments

• Benjamin Sexson, CEO of Monogram Technologies, stated that the funds will provide ample cash runway to meet near-term commercialization milestones.
• Mr. Sexson also noted that the FDA response provides more transparency for Monogram's path forward toward obtaining clearance and ultimately commercialization.
• Mr. Sexson believes the increased clarity regarding the potential suitability of Indian clinical data is de-risking.

Industry Context

The company is operating in the orthopedic robotics market, which is experiencing growth due to advancements in AI, 3D printing, and robotic technologies. The company's focus on personalized knee implants aligns with the trend towards patient-specific solutions in healthcare.

Comparison to Industry Standards

• Monogram's approach to combining AI, 3D printing, and robotics is similar to other companies in the orthopedic robotics space, such as Stryker and Zimmer Biomet, but with a focus on patient-optimized implants.
• The company's mBs system is designed to autonomously execute optimized paths for high-precision insertion of implants, which is a key differentiator compared to traditional surgical methods.
• The company's use of Indian clinical data is a unique approach, and the FDA's feedback on this data will be critical for their regulatory pathway.
• The company's focus on a fully active robotic system is a potential game-changer in the industry, as many current systems are semi-active or require more surgeon intervention.

Stakeholder Impact

• Shareholders will be impacted by the successful capital raise and the potential delay in FDA clearance.
• Employees will be impacted by the company's strategic initiatives and the need to respond to the FDA's request.
• Customers (surgeons and patients) will be impacted by the potential delay in the availability of the mBs TKA System.
• Suppliers and creditors will be impacted by the company's financial position and future plans.

Next Steps

• The company will respond to the FDA's Additional Information Request within 180 days.
• The company will pursue a submission for its active modality with OUS clinical data.
• The company will conduct clinical trials in India with strategic partner Shalby Hospitals.
• The company will conduct OUS live-patient surgery trials and submit clinical trial data to the FDA.
• The company will continue exploring domestic and expanding international relationships.

Key Dates

Keywords

Monogram Technologies, Series D Preferred Stock, FDA, mBs TKA System, Robotics, Orthopedic Surgery, 510(k) Clearance, Capital Raise, Warrants, Clinical Trials